Recent and Ongoing AADAP Research Activities ...

(updated: 18 December 2007)

17α-Methyltestosterone

5 November 2007

Submitted data package to CVM that included:

  1. Final Study Report MT-05-EFF.3-02 describing the effectiveness of 17α-methyltestosterone (MT) medicated feed (60 mg MT/kg fish) to produce predominantly male populations of Nile tilapia.

  2. Final Study Report MT-05-EFF.3-04 describing the effectiveness of MT medicated feed (60 mg MT/kg fish) to produce predominantly male populations of hybrid tilapia.

  3. Multi-Site Summary Report analyzing and summarizing results from three independently conducted MT medicated feed effectiveness studies.

  4. Request that CVM consider the Effectiveness Technical Section complete for the following claim:  Administer MT-medicated feed to larval fish at a dosage of 60 mg MT/kg fish (9 g/kg feed fed at a rate of 15% fish body weight) for 28 days to produce predominantly male populations of tilapia.

December 2007

Environmental Assessment of MT:

AADAP is working with the American Tilapia Association (Kevin Fitzsimmons and Mark Willows) to develop baseline information relative to hatchery discharge in support of an Environmental Assessment for MT.  In cooperation with CVM’s Environmental Team, AADAP developed a survey that will be distributed to tilapia hatcheries via the ATA to collect tilapia hatchery-specific effluent data.

35% PEROX-AID® (Hydrogen Peroxide)

7 November 2007

Submitted the following pivotal study report to CVM:

  1. Final Study Report H2O2-07-EFF-01 describing the effectiveness of 150 mg/L hydrogen peroxide administered daily for 60 min on three consecutive days to control mortality caused by external columnaris in largemouth bass.

19 December 2007

Submitted the Revised Pivotal Efficacy Protocol to CVM:

  1. The efficacy of 35% PEROX-AID®; to control mortality due to bacterial gill disease or external columnaris in cool and warmwater finfish (Protocol
    No. H2O2-07-EFF.1)

Halamid® (Chloramine-T)

14 August 2007

Submitted the following supportive study report to CVM:

  1. Final Study Report CHLT-96-EFF-07 describing the effectiveness of 20 mg/L chloramine-T administered daily for 60 min on three alternate days to control mortality caused by external columnaris in fingerling walleye.

25 September 2007

Submitted the following pivotal study report to CVM:

  1. Final Study Report CHLT-07-EFF.1-0.1 describing the effectiveness of 20 mg/L chloramine-T administered daily for 60 min on three consecutive days to control mortality caused by external columnaris in largemouth bass.

21 November 2007

Submitted data package to CVM that included:

  1. Final Study Report CHLT-07-EFF.1-02 describing the effectiveness of 20 mg/L chloramine-T administered daily for 60 min on three consecutive days to control mortality caused by external columnaris in largemouth bass.

  2. Request that CVM consider the Effectiveness Technical Section complete for the following claim:  Use chloramine-T administered in a static bath or flow-through system at a concentration of 20 mg/L for 60 min/d on three consecutive days to control mortality caused by external columnaris in largemouth bass (additional data to support this claim previously submitted by AADAP).

3 December 2007

Submitted the following manuscript to the Journal of Aquatic Animal Health:

  1. Bowker, J. D., D. Carty, and C. E. Smith.  Safety of repeated chloramine-T exposures to rainbow trout Oncorhynchus mykiss.

Oxytetracycline

10 December 2007

Published the following Drug Research Information Bulletin in the AADAP Publication Series:

  1. Carty, D., J. D. Bowker, M. P. Bowman, and B. Johnson.  Buffering Oxytetracycline Hydrochloride Immersion-Marking Solutions with Sodium Phosphate Dibasic.

Aquaflor® (florfenicol)

4 October 2007

Submitted a request to CVM that they consider the Effectiveness Technical Section complete for the following claim (all data to support this claim previously submitted by AADAP):

  1. Use Aquaflor® administered at a concentration of 10 mg florfenicol per kg fish body weight per day for 10 consecutive days to control mortality of hybrid striped bass caused by Streptococcus iniae.

16 October 2007

Provided an update to the Western Regional Aquaculture Center, Industry Advisory Committee and Technical Committee, Reno, NV:

Year 1 Progress Report.  An evaluation of the effectiveness of various florfenicol treatment regimens to control mortality caused by Streptococcus iniae in hybrid striped bass.

Presented data relative to development of a disease challenge model (Objective #1):

  1. Established baseline information relative to S. iniae immersion and IP injection disease challenge models

  2. Determined the most biologically relevant challenge methodology (immersion or IP injection)

  3. Determined the challenge dose that results in ~ 50% cumulative mortality with minimal variability

  4. Evaluated model reproducibility
Co-principal Investigators: Jim Bowker and Vaughn Ostland; Technical Advisor; Jerri Bartholomew; Extension Agent: Steve Harbell.

27 November 2007

Started the following study:

Evaluation of 10, 15, and 20 mg florfenicol per kg fish body weight per day administered for 10 consecutive days to control mortality in hybrid striped bass experimentally infected with S. iniae.

Jim Bowker and Molly Bowman traveled to Kent SeaTech Corporation’s hybrid striped bass farm near Mecca, CA and worked with Dr. Vaughn Ostland to (1) move test fish into test tanks randomly assigned 1 of 5 treatment conditions (negative control, positive control, or treatments with 10, 15, or 20 mg florfenicol/kg fish body weight), (2) challenge test fish with S. iniae, (3) begin the 10-d feed trial, and (4) conduct sensitivity and MIC testing on cultures of the bacterial working seed.  Dr. Ostland will collect data and conduct fish health evaluations throughout the 10-d treatment and 14-d post-treatment periods.

This study is being conducted as part of the following Western Regional Aquaculture Center funded project:  An evaluation of the effectiveness of various florfenicol treatment regimens to control mortality caused by Streptococcus iniae in hybrid striped bass (Objective #2).

10 December 2007

Published the following AADAP Drug Research Information Bulletin:

  1. D. Carty, J. D. Bowker, M. P. Bowman, and D. A. Erdahl.  Calculate Amount of Aquaflor® (florfenicol, 50%) to Add to Fish Feed.

19 December 2007

  1. Begin florfenicol sensitivity testing of Renibacterium salmoninarum (causative agent of Bacterial Kidney Disease) isolates by Molly Bowman and staff at the USFWS Bozeman Fish Health Center.

AQUI-S®

10 July 2007

Submitted the following GLP-compliant final report to CVM:

  1. Final Study Report AQUIS-06-TAS-FISH.2-01 describing the safety of 40 mg/L AQUI-S®; to sedate cutthroat trout for management and handling purposes.

9 October 2007

Submitted a request that CVM consider the Safety Technical Section complete for the following claim:

  1. Use AQUI-S® to sedate all freshwater salmonids for management and handling purposes (additional safety data on rainbow trout previously submitted to CVM).

10 December 2007

Published the following AADAP Drug Research Information Bulletin:

  1. Carty, D., J. D. Bowker, M. P. Bowman, and B. Johnson.  Modeling the Safety of AQUI-S® to Rainbow Trout Oncorhynchus mykiss.

 

 

 

 
 
Double click to select button
INAD INFORMATION
 
   
©Copyright 2006 US Fish & Wildlife Service All Rights Reserved


 

Disclaimer: Product and company names mentioned in this website, or mentioned in materials accessed via this website, are for informational purposes only. The mention of such does not imply endorsement by the Aquatic Animal Drug Approval Partnership, the U.S. Fish & Wildlife Service or any other organization of the U.S. Government.

For more information, feel free to Contact Us
LAST UPDATED: 16-Jan-2013